In September 2023, Penn spinout BlueWhale Bio surfaced with a mission to advance and improve cell therapy production. BlueWhale raised $18 million in seed financing, led by the venture arm of Danaher Corporation with contributions from Novalis LifeSciences and Marshall Wace.
BlueWhale’s goal is to develop a technology platform and product portfolio that have the potential to bring the benefits of cell therapy to more patients in a way that is quicker and requires lower costs. The company’s scientific team is spearheaded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy and James Riley, PhD., a Professor of Microbiology, both in the Perelman School of Medicine.
Read more about BlueWhale here: